Heegon Kim
NEWS
MARCH 21, 2025
RENATUS’ ALZHEIMER’S RESEARCH PROPELLED BY NATIONAL FUNDING FROM KDRC
Renatus, a company specializing in cholesterol modulators, announced on [date] that it has been selected for a national research project funded by the Korea Dementia Research Center (KDRC). This project will be conducted through a consortium between Ajou University School of Medicine and Renatus.
NOVEMBER 13, 2024
RENATUS PRESENTED PRECLINICAL DATA FROM ITS ALZHEIMER’S DISEASE PROGRAM
Renatus Inc., a pharmaceutical company developing cholesterol modulators to address dysregulated cholesterol homeostasis observed in various diseases, presented preclinical data from its Alzheimer’s disease program at the 2024 Scale-Up Challenge Lab Conference, held on November 6 in Incheon, South Korea.
JULY 12, 2024
RENATUS WAS SELECTED FOR THE MERCK'S 2024 ADVANCE BIOTECH GRANT PROGRAM-KOREA
Renatus Inc., a pharmaceutical company focused on developing cholesterol metabolism modulators, was selected for the Merck’s 2024 Advance Biotech Grant Program – Korea. The Merck’s Advance Biotech Grant Program has recognized innovative biotechnology companies worldwide since 2014.
MARCH 21, 2024
RENATUS HAS BEEN GRANTED A US PATENT FOR CHRONIC KIDNEY DISEASE TREATMENT USING ITS PROPRIETARY CHOLESTEROL METABOLISM MODULATOR
Renatus Inc., a pharmaceutical company focused on developing cholesterol metabolism modulators, today announced the registration of a U.S. patent No. 11931376 entitled “METHODS FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE.”
DECEMBER 26, 2023
RENATUS WAS INTRODUCED ON PAX ECONOMY TV
Renatus, a pharmaceutical company developing cholesterol modulators for the treatment of cholesterol-driven diseases, announced that it was introduced on Pax Economy TV's 'Close-Up of Business', which introduces promising small businesses based in South Korea.
NOVEMBER 22, 2023
RENATUS PRESENTED DATA ON RN-005, A CHOLESTEROL MODULATOR, IN PRECLINICAL CHRONIC KIDNEY DISEASE MODELS AT THE 2023 SCALE-UP CHALLENGE LAB CONFERENCE
Renatus presented data on RN-005, a cholesterol metabolism modulator, in preclinical chronic kidney disease models at the 2023 Scale-up Challenge Lab Conference.
